Wedbush Reiterates Neutral Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Zentalis Pharmaceuticals (NASDAQ:ZNTL)‘s stock had its “neutral” rating reiterated by equities researchers at Wedbush in a note issued to investors on Friday,Benzinga reports. They presently have a $4.00 price objective on the stock. Wedbush’s price objective indicates a potential upside of 120.99% from the stock’s current price.

ZNTL has been the topic of a number of other reports. Wells Fargo & Company reduced their target price on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 30th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Zentalis Pharmaceuticals in a report on Thursday. Finally, UBS Group reduced their price target on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $8.24.

Zentalis Pharmaceuticals Trading Up 1.1 %

Shares of NASDAQ ZNTL opened at $1.81 on Friday. The stock has a fifty day moving average price of $2.04 and a 200 day moving average price of $2.85. Zentalis Pharmaceuticals has a 12-month low of $1.61 and a 12-month high of $16.27. The company has a market cap of $128.99 million, a P/E ratio of -0.73 and a beta of 1.75.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its earnings results on Wednesday, March 26th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.09. The company had revenue of $26.90 million during the quarter. On average, sell-side analysts forecast that Zentalis Pharmaceuticals will post -2.42 EPS for the current fiscal year.

Insider Buying and Selling at Zentalis Pharmaceuticals

In related news, insider Ingmar Bruns purchased 20,000 shares of the company’s stock in a transaction dated Thursday, February 6th. The shares were acquired at an average cost of $2.28 per share, for a total transaction of $45,600.00. Following the transaction, the insider now owns 36,629 shares of the company’s stock, valued at $83,514.12. This trade represents a 120.27 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Jan Skvarka acquired 60,000 shares of Zentalis Pharmaceuticals stock in a transaction that occurred on Friday, January 31st. The shares were bought at an average price of $1.72 per share, with a total value of $103,200.00. Following the transaction, the director now directly owns 149,551 shares in the company, valued at approximately $257,227.72. This trade represents a 67.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 3.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Corton Capital Inc. acquired a new position in shares of Zentalis Pharmaceuticals during the fourth quarter worth approximately $32,000. Captrust Financial Advisors acquired a new stake in Zentalis Pharmaceuticals in the 4th quarter valued at approximately $33,000. Erste Asset Management GmbH acquired a new position in Zentalis Pharmaceuticals during the 3rd quarter worth $37,000. Paloma Partners Management Co acquired a new position in Zentalis Pharmaceuticals during the 3rd quarter worth $37,000. Finally, Prudential Financial Inc. bought a new position in shares of Zentalis Pharmaceuticals in the fourth quarter worth $39,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.